Unknown

Dataset Information

0

Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.


ABSTRACT: Although the starting event in COVID-19 is a viral infection some patients present with an over-exuberant inflammatory response, leading to acute lung injury (ALI) and adult respiratory distress syndrome (ARDS). Since IL-6 plays a critical role in the inflammatory response, we assessed the efficacy and safety of tocilizumab (TCZ) in this single-centre, observational study in all Covid-19 in-patient with a proven SARS-CoV-2 rapidly progressing infection to prevent ALI and ARDS. 104 patients with COVID-19 treated with TCZ had a lower mortality rate (5·8%) compared with the regional mortality rate (11%), hospitalized patient's mortality (10%), and slightly lower than hospitalized patients treated with our standard of care alone (6%). We found that TCZ rapidly decreased acute phase reactants, ferritin and liver release of proteins. D-Dimer decreased slowly. We did not observe specific safety concerns. Early administration of IL6-R antagonists in COVID-19 patients with impending hyperinflammatory response, may be safe and effective treatment to prevent, ICU admission and further complications.

SUBMITTER: Corominas H 

PROVIDER: S-EPMC7658611 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.

Corominas Hèctor H   Castellví Ivan I   Pomar Virginia V   Antonijoan Rosa R   Mur Isabel I   Matas Laia L   Gich Ignasi I   de Benito Natividad N   Laiz Ana A   Castillo Diego D   Villamarin Laura L   Filella David D   Millán Ana Milena AM   Quijada María Ángeles MÁ   Puig Mireia M   Casademont Jordi J   Domingo Pere P  

Clinical immunology (Orlando, Fla.) 20201112


Although the starting event in COVID-19 is a viral infection some patients present with an over-exuberant inflammatory response, leading to acute lung injury (ALI) and adult respiratory distress syndrome (ARDS). Since IL-6 plays a critical role in the inflammatory response, we assessed the efficacy and safety of tocilizumab (TCZ) in this single-centre, observational study in all Covid-19 in-patient with a proven SARS-CoV-2 rapidly progressing infection to prevent ALI and ARDS. 104 patients with  ...[more]

Similar Datasets

| S-EPMC7449935 | biostudies-literature
| S-EPMC7524533 | biostudies-literature
| S-EPMC7329292 | biostudies-literature
| S-EPMC7524518 | biostudies-literature
| S-EPMC7242960 | biostudies-literature
| S-EPMC6477522 | biostudies-literature
| S-EPMC4717437 | biostudies-literature
| S-EPMC7425928 | biostudies-literature
| S-EPMC6878843 | biostudies-literature
| S-EPMC9068500 | biostudies-literature